Jinshi Pharmaceutical Co., Ltd.
金石亚药
300434
Shenzhen Stock Exchange
Key Financials
Announcements
Legal Opinion on the 2025 Annual Shareholders Meeting of Jinshiyao by Beijing Tianchi Juntai Law Firm
Announcement of Resolutions from the 2025 Annual Shareholders' Meeting
Pre-disclosure Announcement on Directors' Share Reduction
Announcement on Using Idle Self-Owned Funds for Entrusted Wealth Management
Announcement on Requesting Shareholders' Meeting to Authorize the Board to Issue Stocks to Specific Objects via Simplified Procedures
Announcement on the Proposed Reappointment of Financial Audit and Internal Control Audit Institutions for 2026
Announcement on Changing the Signing Registered Accountant
2025 Annual Independent Director Work Report (Zhong Peng)
2025 Annual Independent Director Work Report (Jia Youlong)
2025 Annual Independent Director Work Report (Zhao Xiaowei)
2025 Annual Independent Director Work Report (Liu Chuwang)
Announcement on Holding the 2025 Annual Online Performance Briefing
2025 Annual Internal Control Audit Report
2025 Annual Internal Control Self-Evaluation Report
Annual Performance Incentive Management System (April 2026)
Director and Senior Management Compensation Management System (April 2026)
Major Information Internal Reporting System (April 2026)
Notice of the 2025 Annual Shareholders' Meeting
Announcement of the Fifth Board's Twelfth Meeting Resolution
Announcement on the Confirmation of Director and Senior Management Compensation for 2025 and Compensation Plan for 2026
Announcement on the Company's Application for Comprehensive Credit Line from Banks and Financial Institutions
2025 Annual Board Work Report
Audit Committee 2025 Performance Report
Announcement on the 2025 Annual Profit Distribution Plan
2026 Q1 Report
Company's Evaluation Report on the Accounting Firm's Performance in 2025
Board Audit Committee Report on the Evaluation of the Accounting Firm's Performance in 2025 and Supervision Responsibilities
Special Report on Non-Operating Fund Occupation and Other Related Fund Transactions
Goodwill Impairment Test Report
2025 Annual Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions
Proposed Impairment Test for Goodwill Arising from the Merger with Zhejiang Jian De Zhengfa Pharmaceutical Co., Ltd. Asset Group Recoverable Value Assessment Report
Proposed Impairment Test for Goodwill Arising from the Merger with Hainan Asia Pharmaceutical Co., Ltd. Asset Group Recoverable Value Assessment Report
Notes & Comments
Sign in to leave a comment or private note.
Loading…